Imatinib (QTI571) in Pulmonary Arterial Hypertension
Public ClinicalTrials.gov record NCT00902174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
Study identification
- NCT ID
- NCT00902174
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 202 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2009 (Type not available)
- Primary completion
- May 2011 (Actual)
- Completion
- May 2011 (Actual)
- Last update posted
- Feb 17, 2016
2009 – 2011
United States locations
- U.S. sites
- 33
- U.S. states
- 21
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35294 | — |
| Novartis Investigative Site | Phoenix | Arizona | 85013 | — |
| Novartis Investigative Site | Los Angeles | California | 90024 | — |
| Novartis Investigative Site | San Francisco | California | 94143 | — |
| Novartis Investigative Site | Aurora | Colorado | 80045 | — |
| Novartis Investigative Site | Clearwater | Florida | 33756 | — |
| Novartis Investigative Site | Miami Beach | Florida | 33140 | — |
| Novartis Investigative Site | Weston | Florida | 33331 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30342 | — |
| Novartis Investigative Site | Chicago | Illinois | 60637 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21205 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02111 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02114 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02118 | — |
| Novartis Investigative Site | Rochester | Minnesota | 55905 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68131 | — |
| Novartis Investigative Site | Minneola | New York | 11501-3893 | — |
| Novartis Investigative Site | New York | New York | 10029 | — |
| Novartis Investigative Site | New York | New York | 10032 | — |
| Novartis Investigative Site | Durham | North Carolina | 27710 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45219 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44106 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44195 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73104 | — |
| Novartis Investigative Site | Portland | Oregon | 97210 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19140 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15212 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15213 | — |
| Novartis Investigative Site | Knoxville | Tennessee | 37934 | — |
| Novartis Investigative Site | Dallas | Texas | 75390 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00902174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2016 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00902174 live on ClinicalTrials.gov.